Search NASA⌕ Search

SEARCH · Search NASA

Results for “Biomedical support”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 397 records · Page 22
All sourcesNASA NTRSDOE OSTI
NASA NTRSDate not supplied

Transformation of the NASA Life Sciences Portal to a FAIR Data Point

The FAIR principles emphasize optimizing metadata, the vast majority of which are textual in nature, and often organized into attribute name-value pairs. This uniformity has led to the development of guidelines and best practices for providing programmatic access to scientific data through their metadata, yielding the first iteration of the FAIR Data Point Specifications (FDPS). A key feature of the FDPS is its support for automated agents seeking and fetching data without first needing to learn a plethora of different application programming interfaces. These software agents can interrogate metadata catalogs that adhere to FDPS in a uniform manner because each catalog describes itself and its metadata schema consistently. This approach enhances the sustainability of data retrieval support, allowing systems to refine and update their metadata schemas as needed and without requiring data-seeking software agents to change how they interrogate FDPS catalogs. An essential aspect of the FDPS is the standardization of data catalog semantics, which formalizes concepts such as “metadata” and “metadata service” and links them to other concepts specifications including the Data Catalog Vocabulary (DCAT), a W3C standard that is also the basis of NASA-STD-2831 “Metadata Standard for Data Discoverability,” authored by NASA’s Office of the Chief Information Officer. The FDPS references DCAT (version 2) elements which focus on the distribution of datasets and support the goal of stream-lined catalog integration across repositories for improved data discovery. Additionally, the FDPS also prescribe the use of Linked Data Platform elements for data catalog-metadata record containment descriptions, allowing users to ascertain which data and metadata belong to which catalogs. NASA’s Life Sciences Portal is implementing the FDPS while formalizing its metadata schema to support the accelerated synthesis of knowledge from space life sciences investigations.

platform↗
NASA NTRS2003

Evidence for altered alpha-adrenoreceptor responsiveness after a single bout of maximal exercise

We studied hemodynamic responses to alpha- and beta-receptor agonists in eight men to test the hypothesis that adrenoreceptor responsiveness is altered within 24 h of the performance of maximal exercise. Adrenoreceptor responsiveness was tested under two experimental conditions (with and without maximal exercise). Adrenoreceptor tests were performed 24 h after each subject performed graded upright cycle ergometry to volitional exhaustion. The 2 test days (experimental conditions) were separated by at least 1 wk, and the order of exercise and no-exercise conditions was counterbalanced. Steady-state graded infusions of phenylephrine (PE) and isoproterenol (Iso) were used to assess alpha- and beta-adrenoreceptor responsiveness, respectively. Slopes calculated from linear regressions between Iso and PE doses and changes in heart rate, blood pressure, and leg vascular resistance for each subject were used as an index of alpha- and beta-adrenoreceptor responsiveness. The slope of the relationship between heart rate and Iso with maximal exercise was 1773 +/- 164 beats x microm-1x kg-1x min-1 compared with 1987 +/- 142 beats x microg-1x kg-1x min-1 without exercise (P = 0.158), whereas the slopes of the relationship between vascular resistance to Iso were -438 +/- 123 peripheral resistance units (PRU) x microg-1x kg-1x min-1 with maximal exercise and -429 +/- 105 x microg-1x kg-1 x min-1 without exercise (P = 0.904). Maximal exercise was associated with greater (P < 0.05) vascular resistance (15.1 +/- 2.8 PRU x microg-1 kg-1x min-1) and mean arterial blood pressure (15.8 +/- 2.1 mmHg. microg-1x kg-1x min-1) responses to PE infusion compared with no exercise (9.0 +/- 2.0 PRU x microg-1 kg-1 x min-1 and 10.9 +/- 2.0 mmHg. microg-1x kg-1x min-1, respectively). These results provide evidence that a single bout of maximal exercise increases alpha1-adrenoreceptor responsiveness within 24 h without affecting beta-cardiac and vascular adrenoreceptor responses.

Non-NASA Center↗
NASA NTRS1999

Nutrition and muscle loss in humans during spaceflight

The protein loss in humans during spaceflight is partly due to a normal adaptive response to a decreased work load on the muscles involved in weight bearing. The process is mediated by changes in prostaglandin release, secondary to the decrease in tension on the affected muscles. On missions, where there is a high level of physical demands on the astronauts, there tends to be an energy deficit, which adds to the muscle protein loss and depletes the body fat reserves. While the adaptive response is a normal part of homeostasis, the additional protein loss from an energy deficit can, in the long run, have a negative effect on health and capability of humans to live and work in space and afterward return to Earth.

NASA Program Biomedical Research and Countermeasur↗
NASA NTRS2000

Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function

BACKGROUND: Hypertension is a major independent risk factor for cardiac deaths, and diastolic dysfunction is a usual finding during the course of this disease. HYPOTHESIS: This study was designed to investigate the effects of chronic therapy with perindopril on left ventricular (LV) mass, left atrial size, diastolic function, and plasma level of atrial natriuretic peptide (ANP) in patients with hypertension. METHODS: Twenty four patients who had not been previously taking any antihypertensive medication and without prior history of angina pectoris, myocardial infarction, congestive heart failure, dysrhythmias, valvular heart disease, or systemic illnesses received 4-8 mg/day of perindopril orally. Echocardiographic studies were acquired at baseline and 6 months after the initiation of therapy. RESULTS: Systolic and diastolic blood pressure decreased from 174 +/- 19.7 and 107.5 +/- 7.8 mmHg to 134 +/- 10.6 and 82 +/- 6.7 mmHg, respectively (p < 0.001). Left ventricular mass decreased from 252.4 +/- 8.3 to 205.7 +/- 7.08 g and left atrial volume from 20.4 +/- 5.1 to 17.6 +/- 5.2 ml, respectively (p < 0.001). Transmitral Doppler early and atrial filling velocity ratio (E/A) increased from 0.69 +/- 0.06 to 0.92 +/- 0.05 m/s and plasma ANP level decreased from 71.9 +/- 11.7 to 35.3 +/- 7.8 pg/ml (p < 0.001). Reduction of LV mass correlated positively with a reduction in ANP levels (r = 0.66, p < 0.0005). CONCLUSIONS: Perindopril caused a significant reduction of LV mass, left atrial volume, and plasma ANP levels, as well as improvement in Doppler parameters of LV filling in this group of patients with hypertension.

NASA Program Biomedical Research and Countermeasur↗
NASA NTRS2003

Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. II. Activation, cytokines, erythrocytes, and platelets

This portion of the study quantified the effects of a 12-day space shuttle mission (Space Transport System-108/UF-1) on body and lymphoid organ masses, activation marker expression, cytokine secretion, and erythrocyte and thrombocyte characteristics in C57BL/6 mice. Animals in flight (Flt group) had 10-12% lower body mass compared with ground controls housed either in animal enclosure modules or under standard vivarium conditions (P < 0.001) and the smallest thymus and spleen masses. Percentages of CD25(+) lymphocytes, CD3(+)/CD25(+) T cells, and NK1.1(+)/CD25(+) natural killer cells from Flt mice were higher compared with both controls (P < 0.05). In contrast, CD71 expression was depressed in the Flt and animal enclosure module control mice compared with vivarium control animals (P < 0.001). Secretion of interferon-gamma, IL-2, and IL-4, but not tumor necrosis factor-alpha and IL-5, by splenocytes from Flt mice was decreased relative to either one or both ground controls (P < 0.05). Flt mice also had high red blood cell and thrombocyte counts compared with both sets of controls; low red blood cell volume and distribution width, percentage of reticulocytes, and platelet volume were also noted (P < 0.05) and were consistent with dehydration. These data indicate that relatively short exposure to the spaceflight environment can induce profound changes that may become significant during long-term space missions.

Flight Experiment↗
NASA NTRS2004

The effects of proton exposure on neurochemistry and behavior

Future space missions will involve long-term travel beyond the magnetic field of the Earth, where astronauts will be exposed to radiation hazards such as those that arise from galactic cosmic rays. Galactic cosmic rays are composed of protons, alpha particles, and particles of high energy and charge (HZE particles). Research by our group has shown that exposure to HZE particles, primarily 600 MeV/n and 1 GeV/n 56Fe, can produce significant alterations in brain neurochemistry and behavior. However, given that protons can make up a significant portion of the radiation spectrum, it is important to study their effects on neural functioning and on related performance. Therefore, these studies examined the effects of exposure to proton irradiation on neurochemical and behavioral endpoints, including dopaminergic functioning, amphetamine-induced conditioned taste aversion learning, and spatial learning and memory as measured by the Morris water maze. Male Sprague-Dawley rats received a dose of 0, 1.5, 3.0 or 4.0 Gy of 250 MeV protons at Loma Linda University and were tested in the different behavioral tests at various times following exposure. Results showed that there was no effect of proton irradiation at any dose on any of the endpoints measured. Therefore, there is a contrast between the insignificant effects of high dose proton exposure and the dramatic effectiveness of low dose (<0.1 Gy) exposures to 56Fe particles on both neurochemical and behavioral endpoints. Published by Elsevier Ltd on behalf of COSPAR.

Non-NASA Center↗
NASA NTRS2024

NASA's Human Research Program: Evolving Collaborations to Enable the Future of Human Spaceflight

Since its formation in 2007, the NASA Human Research Program’s (HRP) mission has been to protect the health and performance of astronauts as they explore beyond low Earth orbit. The HRP helps enable exploration spaceflight through a focused program of research that leads to the development and delivery of solutions to protect human health and performance during and after these missions. This research is conducted primarily in ground analogs of the spaceflight environment and on the International Space Station (ISS). Over the last 3 years, NASA has undergone transformative changes with the flight of Artemis I, the formation of the Commercial Low Earth Orbit Destinations Program, commercial flights to the ISS, and collaboration with new international partners participating in human spaceflight. The HRP has embraced these new opportunities and is collaborating on all these fronts to collect biomedical research data. Artemis I marked the arrival of NASA’s new human spaceflight exploration missions. NASA established the Moon to Mars Program Office to design a roadmap for the exploration of the lunar surface and the journey beyond to Mars. The HRP has a critical role in conducting research and delivering technologies that will lead to solutions that protect human health and performance, and is working closely with the Moon to Mars Office to ensure these deliverables are ready in time to support their strategy. The HRP is also developing the partnership strategies required to support these deliverables. Commercial space flights, both free flyer and suborbital missions and private astronaut missions to the ISS, are providing broader opportunities and more subjects to characterize spaceflight-induced changes to the human system and to test countermeasures. To better use these opportunities to achieve its mission, the HRP has been working to understand the commercial spaceflight companies’ needs and then partnering with them on aspects of mutual interest. In addition, the HRP continues to engage in long-standing relationships with its international partners through the International Space Life Sciences Working Group and other joint international groups. The HRP is interested in sharing its knowledge and collaborating on projects of mutual interest with new countries that are developing capabilities for human spaceflight. The next 10 years will shape how humanity partners on exploration missions to Mars, and the HRP is committed to enabling and developing collaborative strategies with commercial and international partners to keep humans safe and productive as they explore longer and further into space.

Human research↗
NASA NTRS1988

Angiotensin converting enzyme inhibition and the kidney

Angiotensin II (Ang II) induces a marked reduction in renal blood flow at doses well below those required to induce a pressor response, and as blood flow falls there is a decline in glomerular filtration rate and sodium excretion. This striking sensitivity of the renal blood supply led many workers to consider the possibility that angiotensin functions as a local renal hormone. As angiotensin converting enzyme (ACE) was found in particular abundance in the lung, it seemed reasonable to suspect that most of the conversion occurred there, and that the function of Ang II would be primarily systemic, rather than intrarenal. In this review, I will explore the evidence that has accumulated on these two possibilities, since they have important implications for our current understanding of normal kidney function and derangements of kidney function in disease.

NASA Program Biomedical Research↗
NASA NTRS1991

Biomedical applications of NASA technology

Through the active transfer of technology, NASA Technology Utilization (TU) Program assists private companies, associations, and government agencies to make effective use of NASA's technological resources to improve U.S. economic competitiveness and to provide societal benefit. Aerospace technology from such areas as digital image processing, space medicine and biology, microelectronics, optics, and electro-optics, and ultrasonic imaging have found many secondary applications in medicine. Examples of technology spinoffs are briefly discussed to illustrate the benefits realized through adaptation of aerospace technology to solve health care problems. Successful implementation of new technologies increasingly requires the collaboration of industry, universities, and government and the TU Program serves as the liaison to establish such collaborations with NASA. NASA technology is an important resource to support the development of new medical products and techniques that will further advance the quality of health care available in the U.S. and worldwide.

Friedman, Donald S.↗
NASA NTRS2016

Exploration Laboratory Analysis

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability (ExMC) risk to minimize or reduce the risk of adverse health outcomes and decrements in performance due to in-flight medical capabilities on human exploration missions. To mitigate this risk, the availability of inflight laboratory analysis instrumentation has been identified as an essential capability for manned exploration missions. Since a single, compact space-ready laboratory analysis capability to perform all exploration clinical measurements is not commercially available, the ELA project objective is to demonstrate the feasibility of emerging operational and analytical capability as a biomedical diagnostics precursor to long duration manned exploration missions. The initial step towards ground and flight demonstrations in fiscal year (FY) 2015 was the downselection of platform technologies for demonstrations in the space environment. The technologies selected included two Small Business Innovation Research (SBIR) performers: DNA Medicine Institute's rHEALTH X and Intelligent Optical System's lateral flow assays combined with Holomic's smartphone analyzer. The selection of these technologies were based on their compact size, breadth of analytical capability and favorable ability to process fluids in a space environment, among several factors. These two technologies will be advanced to meet ground and flight demonstration success criteria and requirements. The technology demonstrations and metrics for success will be finalized in FY16. Also, the downselected performers will continue the technology development phase towards meeting prototype deliverables in either late 2016 or 2017.

In-Flight laboratory↗
NASA NTRS2016

Exploration Laboratory Analysis

The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability (ExMC) risk to minimize or reduce the risk of adverse health outcomes and decrements in performance due to in-flight medical capabilities on human exploration missions. To mitigate this risk, the availability of inflight laboratory analysis instrumentation has been identified as an essential capability for manned exploration missions. Since a single, compact space-ready laboratory analysis capability to perform all exploration clinical measurements is not commercially available, the ELA project objective is to demonstrate the feasibility of emerging operational and analytical capability as a biomedical diagnostics precursor to long duration manned exploration missions. The initial step towards ground and flight demonstrations in fiscal year (FY) 2015 was the down selection of platform technologies for demonstrations in the space environment. The technologies selected included two Small Business Innovation Research (SBIR) performers: DNA Medicine Institutes rHEALTH X and Intelligent Optical Systems later flow assays combined with Holomics smartphone analyzer. The selection of these technologies were based on their compact size, breadth of analytical capability and favorable ability to process fluids in a space environment, among several factors. These two technologies will be advanced to meet ground and flight demonstration success criteria and requirements that will be finalized in FY16. Also, the down selected performers will continue the technology development phase towards meeting prototype deliverables in either late 2016 or 2017.

Laboratory analysis↗
NASA NTRS1994

Annual program analysis of the NASA Space Life Sciences Research and Education Support Program

The basic objectives of this contract are to stimulate, encourage, and assist research and education in NASA life sciences. Scientists and experts from a number of academic and research institutions in this country and abroad are recruited to support NASA's need to find a solution to human physiological problems associated with living and working in space and on extraterrestrial bodies in the solar system. To fulfill the contract objectives, a cadre of staff and visiting scientists, consultants, experts, and subcontractors has been assembled into a unique organization dedicated to the space life sciences. This organization, USRA's Division of Space Life Sciences, provides an academic atmosphere, provides an organizational focal point for science and educational activities, and serves as a forum for the participation of eminent scientists in the biomedical programs of NASA. The purpose of this report is to demonstrate adherence to the requirement of Contract NAS9-18440 for a written review and analysis of the productivity and success of the program. In addition, this report makes recommendations for future activities and conditions to further enhance the objectives of the program and provides a self-assessment of the cost performance of the contract.

Source record↗
NASA NTRS2000

Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice

Obesity is a major health care problem and is associated with significant cardiovascular morbidity. Leptin, a neuroendocrine hormone released by adipose tissue, is important in modulating obesity by signaling satiety and increasing metabolism. Moreover, leptin receptors are expressed on vascular endothelial cells (ECs) and mediate angiogenesis. We hypothesized that leptin may also play an important role in vasoregulation. We investigated vasoregulatory mechanisms in the leptin-deficient obese (ob/ob) mouse model and determined the influence of leptin replacement on endothelial-dependent vasorelaxant responses. The direct effect of leptin on EC nitric oxide (NO) production was also tested by using 4, 5-diaminofluorescein-2 diacetate staining and measurement of nitrate and nitrite concentrations. Vasoconstrictor responses to phenylephrine, norepinephrine, and U-46619 were markedly enhanced in aortic rings from ob/ob mice and were modulated by NO synthase inhibition. Vasorelaxant responses to ACh were markedly attenuated in mesenteric microvessels from ob/ob mice. Leptin replacement resulted in significant weight loss and reversal of the impaired endothelial-dependent vasorelaxant responses observed in ob/ob mice. Preincubation of ECs with leptin enhanced the release of NO production. Thus leptin-deficient ob/ob mice demonstrate marked abnormalities in vasoregulation, including impaired endothelial-dependent vasodilation, which is reversed by leptin replacement. These findings may be partially explained by the direct effect of leptin on endothelial NO production. These vascular abnormalities are similar to those observed in obese, diabetic, leptin-resistant humans. The ob/ob mouse may, therefore, be an excellent new model for the study of the cardiovascular effects of obesity.

NASA Program Biomedical Research and Countermeasur↗
NASA NTRSDate not supplied

Standard measures in Analogs of Spaceflight

Standard measures are defined as research measures (physiological, performance, or otherwise) that quantify the subject’s health and performance before, during, and after a spaceflight or a spaceflight analog mission. The Standard Measures Cross-Cutting Project (SMCCP) collects and analyzes standard measures that support assessment and quantification of health risks and efficacy of countermeasures and technologies required to prevent or mitigate adverse outcomes from exposure to the spaceflight environment. SMCCP uses the following spaceflight analogs: - Human Exploration Research Analog (HERA) in Houston, TX: 4-person isolation/confinement; nominal mission duration of 45 days; run by the Human Research Program (HRP). SMCCP uses weekly questionnaires to gather data on the crewmembers’ emotional and mental state and collects blood samples biweekly to measure crewmembers’ serum cortisol levels at the start, middle, and end of the mission. - Institute for Biomedical Problems (IBMP) Ground-Based Experimental Complex, called NEK, in Moscow, Russia: 6-person isolation/confinement; duration of 8 months; run by IBMP. Standard measures data collected during NEK are the same as for HERA above. - :envihab in Cologne, Germany: 12-person bed rest facility; closed environment; 30 to 60-day campaigns; run by the German Aerospace Center (DLR). For bedrest studies, SMCCP uses the international standard measures as documented in the International Academy of Astronautics publication titled Guidelines for Standardization of Bed Rest Studies in the Spaceflight Context (June 2014). These international standard measures evaluate potential changes in bone, muscle, cardiovascular, and visual systems, as well as changes in psychology and nutrition. The international standard measures complement those collected during studies by individual investigators and allow comparison of responses across different bed rest and countermeasures durations. In this presentation, we will review available SMCCP data collected during the recent isolation studies in HERA (C6) and NEK (SIRIUS-21), and during the SANS (SM1, SM2) bed rest studies in :envihab. These standard measures datasets are made available to concurrent investigators in the given mission or campaign via data sharing agreements and/or data sharing plans and to other investigators that have been granted retrospective access to the data (researchers with IRB approved protocols, risk custodians) to advance understanding of physiological and behavioral risks associated with these spaceflight analogs.

Standard Measures↗
NASA NTRS2010

Health Maintenance System (HMS) Hardware Research, Design, and Collaboration

The Space Life Sciences division (SLSD) concentrates on optimizing a crew member's health. Developments are translated into innovative engineering solutions, research growth, and community awareness. This internship incorporates all those areas by targeting various projects. The main project focuses on integrating clinical and biomedical engineering principles to design, develop, and test new medical kits scheduled for launch in the Spring of 2011. Additionally, items will be tagged with Radio Frequency Interference Devices (RFID) to keep track of the inventory. The tags will then be tested to optimize Radio Frequency feed and feed placement. Research growth will occur with ground based experiments designed to measure calcium encrusted deposits in the International Space Station (ISS). The tests will assess the urine calcium levels with Portable Clinical Blood Analyzer (PCBA) technology. If effective then a model for urine calcium will be developed and expanded to microgravity environments. To support collaboration amongst the subdivisions of SLSD the architecture of the Crew Healthcare Systems (CHeCS) SharePoint site has been redesigned for maximum efficiency. Community collaboration has also been established with the University of Southern California, Dept. of Aeronautical Engineering and the Food and Drug Administration (FDA). Hardware disbursements will transpire within these communities to support planetary surface exploration and to serve as an educational tool demonstrating how ground based medicine influenced the technological development of space hardware.

Gonzalez, Stefanie M.↗
NASA NTRS2024

NASA's Human Research Program: Evolving Collaborations to Enable the Future of Human Spaceflight

Since its formation in 2007, the NASA Human Research Program’s (HRP) mission has been to reduce human health and performance risks for spaceflight exploration missions. The program has achieved this mission primarily through work in ground analogs and on the International Space Station. Over the last three years, NASA overall has seen transformative changes with the flight of Artemis I, formation of the Commercial LEO Destinations Program, commercial flights to the ISS, and new International Partners participating in human spaceflight. NASA’s HRP has embraced these new opportunities and is collaborating on all these fronts to collect biomedical research data. Artemis I marked the arrival of NASA’s new human spaceflight exploration missions. NASA has developed a Moon-to-Mars Architecture to map out how it will use the moon to de-risk and enable Mars missions. NASA’s HRP is a critical component to develop and deliver research and technologies for future Artemis Crew Health and Performance (CHP) Systems. The program is working closely with NASA’s Moon-to-Mars Office to ensure CHP deliverables are ready to demonstrate on the moon, as we also look toward Mars, and is developing the partnership strategies required to support these deliverables. Commercial space flights, both free flyer and suborbital missions and private astronaut missions to the ISS, are providing broader opportunities and subjects to characterize the space-induced changes to the human system and to test countermeasures. To better use these opportunities to achieve its mission, HRP has been working to understand the commercial spaceflight companies’ needs and then partner with them on aspects of mutual interest. In addition, NASA HRP continues to engage in long-standing relationships with its international partners through the International Space Life Sciences Working Group (ISLSWG) and other joint international groups. The Program is now also interested in sharing its knowledge and ability to collaborate on projects of mutual interest with new countries developing capabilities for human spaceflight. The next 10 years will shape how humanity partners on exploration missions to Mars. NASA’s HRP is committed to enabling and developing collaborative strategies with commercial and international partners to keep humans safe and productive as we explore longer and further into space.

Jancy McPhee↗
NASA NTRS2001

New measurements for hadrontherapy and space radiation: biology

The dual goals of optimizing clinical efficacy of hadrontherapy and determining radiation risk estimates for space research have intersected to a common focus for investigation of the biological effects of charged particles. This paper briefly highlights recent international progress at accelerator facilities engaged in both biological and clinical studies of the effects of particle beams, primarily protons, carbon and iron ions. Basic mechanisms of molecular, cellular and tissue responses continue under investigation for radiations with a range of ionization densities. Late normal tissue effects, including the risk of cancer in particular, are of importance for both research fields. International cooperation has enhanced the rate of progress as evidenced by recent publications. Specific areas of biomedical research related to the biological radiotoxicity of critical organs (especially the central nervous system), individual radiosensitivities to radiation carcinogenesis, and the analysis of effects in mixed radiation fields still require more research. Recommendations for addressing these issues are made.

Review↗
NASA NTRS1992

Opportunities for research on Space Station Freedom

NASA has allocated research accommodations on Freedom (equipment, utilities, etc.) to the program offices that sponsor space-based research and development as follows: Space Science and Applications (OSSA)--52 percent, Commercial Programs (OCP)--28 percent, Aeronautics and Space Technology (OAST)--12 percent, and Space Flight (OSF)--8 percent. Most of OSSA's allocation will be used for microgravity and life science experiments; although OSSA's space physics, astrophysics, earth science and applications, and solar system exploration divisions also will use some of this allocation. Other Federal agencies have expressed an interest in using Space Station Freedom. They include the National Institutes of Health (NIH), U.S. Geological Survey, National Science Foundation, National Oceanic and Atmospheric Administration, and U.S. Departments of Agriculture and Energy. Payload interfaces with space station lab support equipment must be simple, and experiment packages must be highly contained. Freedom's research facilities will feature International Standard Payload Racks (ISPR's), experiment racks that are about twice the size of a Spacelab rack. ESA's Columbus lab will feature 20 racks, the U.S. lab will have 12 racks, and the Japanese lab will have 10. Thus, Freedom will have a total of 42 racks versus 8 for Space lab. NASA is considering outfitting some rack space to accommodate small, self-contained payloads similar to the Get-Away-Special canisters and middeck-locker experiment packages flown on Space Shuttle missions. Crew time allotted to experiments on Freedom at permanently occupied capability will average 25 minutes per rack per day, compared to six hours per rack per day on Spacelab missions. Hence, telescience--the remote operation of space-based experiments by researchers on the ground--will play a very important role in space station research. Plans for supporting life sciences research on Freedom focus on the two basic goals of NASA 's space life sciences program: to ensure the health, safety, and productivity of humans in space and to acquire fundamental knowledge of biological processes. Space-based research has already shown that people and plants respond the same way to the microgravity environment: they lose structure. However, the mechanisms by which they respond are different, and researchers do not yet know much about these mechanisms. Life science research accommodations on Freedom will include facilities for experiments designed to address this and other questions, in fields such as gravitational biology, space physiology, and biomedical monitoring and countermeasures research.

Phillips, Robert W.↗